Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct:34:108-121.
doi: 10.1016/j.jtos.2024.07.001. Epub 2024 Jul 5.

Mpox Virus and its ocular surface manifestations

Affiliations
Review

Mpox Virus and its ocular surface manifestations

Nikhil Chakravarty et al. Ocul Surf. 2024 Oct.

Abstract

The Mpox virus (MPXV) is the causative agent of human Mpox disease - a debilitating rash illness similar to smallpox. Although Clade I MPXV has remained endemic to West and Central Africa, Clade II MPXV has been responsible for many outbreaks worldwide. The most recent outbreak in 2022 resulted from the rapid spread of a new clade of MPXV, classified into Clade IIb - a distinct lineage from the previously circulating viral strains. The rapid spread and increased severity of Mpox disease by the Clade IIb strain have raised the serious public health imperative of better understanding the host and viral determinants during MPXV infection. In addition to typical skin rashes, including in the periorbital area, MPXV causes moderate to severe ophthalmic manifestations - most commonly, ocular surface complications (e.g., keratitis, conjunctivitis, blepharitis). While ocular manifestations of Clade I Mpox within the Congo basin have been well-reported, global incidence trends of ocular Mpox cases by Clade IIb are still emerging. Given the demonstrated ability of all MPXV strains to auto-inoculate ocular tissue, alongside the enhanced transmissibility of the Clade IIb virus, there is an urgent need to elucidate the mechanisms by which MPXV causes ocular anomalies. In this review, we discuss the viral and genomic structures of MPXV, the epidemiology, and pathology of systemic and ocular Mpox, as well as potential prophylactic and therapeutic interventions.

Keywords: Cidofovir; Monkeypox; Mpox; Ocular; Ophthalmic; Orthopoxvirus; Tecovirimat (TPOXX).

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors have no conflicts of interest to disclose.

Similar articles

Cited by

References

    1. Adler H, Gould S, Hine P, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis 2022;22(8):1153–1162. doi:10.1016/S1473-3099(22)00228-6 - DOI - PMC - PubMed
    1. Rabaan AA, Al-Shwaikh SA, Alfouzan WA, et al. A Comprehensive Review on Monkeypox Viral Disease with Potential Diagnostics and Therapeutic Options. Biomedicines. 2023;11(7):1826. doi:10.3390/biomedicines11071826 - DOI - PMC - PubMed
    1. Hutin YJ, Williams RJ, Malfait P, et al. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg Infect Dis 2001;7(3):434–438. doi:10.3201/eid0703.010311 - DOI - PMC - PubMed
    1. Amer F, Khalil HES, Elahmady M, et al. Mpox: Risks and approaches to prevention. J Infect Public Health. 2023;16(6):901–910. doi:10.1016/j.jiph.2023.04.001 - DOI - PMC - PubMed
    1. Likos AM, Sammons SA, Olson VA, et al. A tale of two clades: monkeypox viruses. Journal of General Virology. 2005;86(10):2661–2672. doi:10.1099/vir.0.81215-0 - DOI - PubMed

MeSH terms

LinkOut - more resources